These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of plasma freezing temperature, anticoagulant and time of storage on factor VIII:C activity in cryoprecipitate.
    Author: Piedras J, Sánchez-Montero PE, Herrera FM, Córdova MS, Sánchez-Medal L.
    Journal: Arch Med Res; 1993; 24(1):23-6. PubMed ID: 8292873.
    Abstract:
    The influence of ACD and CPDA-1 anticoagulants, and storage time for 3 and 6 months on F VIII:C activity were compared in cryoprecipitate obtained at -70 degrees C, and -30 degrees C plasma freezing temperature. To eliminate variations in F VIII:C activity between donor plasma, the cryoprecipitation at -70 degrees C and -30 degrees C was made in paired plasma volumes (approximately 100 ml) from each blood unit. Employing ACD plasmas (n = 50), there was no significant difference in F VIII:C activity between cryoprecipitate prepared at -70 degrees C (mean = 31.1 IU/bag) and -30 degrees C (X = 30.5 IU/bag), and the storage did not modify F VIII:C activity. In contrast, in cryoprecipitate prepared from CPDA-1 plasmas (n = 31), the F VIII:C levels obtained at -30 degrees C (mean = 43.8 IU/bg) were significantly higher than those at -70 degrees C (mean = 37.3 IU/bag), but a deterioration of F VIII:C activity (about 50%) was observed after 6 months of cryoprecipitate storage. Therefore, if cryoprecipitate is stored it would be more convenient to use ACD instead of CPDA-1 and make cryoprecipitation either at -70 degrees C or -30 degrees C.
    [Abstract] [Full Text] [Related] [New Search]